NCT04961619Completed
Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.
A Real-life Study to Evaluate the Use of Adjuvant Treatment With Dabrafenib and Trametinib in Routine Practice in Patients With Completely Resected High-risk Stage III Melanoma
Source: ClinicalTrials.gov · Last updated 12 Dec 2025
Brief summary (registry, in English)
Non-interventional (observational) cohort prospective real life study with primary and secondary data collection from patients on adjuvant treatment with dabrafenib + trametinib in patients with completely resected high-risk stage III (stage IIIA \[lymph node \> 1mm\], IIIB, IIIC and IIID according to AJCC 8th edition) melanoma in Turkey.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 39 (actual)
- First submitted
- 5 Jul 2021
- Start date
- 1 Dec 2021
- Primary completion date
- 5 Dec 2024
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Melanoma
- NCT number
- NCT04961619
What you commit to
- Study type: Observational
- Participants enrolled: 39
- From 1 Dec 2021 to the primary completion date, 5 Dec 2024
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Current primary diagnosis of a cancer other than melanoma, that requires systemic or other treatment.
Other
- Lack of basic demographic and staging data.
- Current active participation in an interventional clinical trial for treatment of melanoma.
- Pregnancy or breastfeeding women.
Who the study is looking for
- Patients with complete surgical resection of histologically confirmed AJCC (8th edition) clinical stage III (stage IIIA \[lymph node \> 1mm\],, IIIB, IIIC, IIID) melanoma, in whom a decision for adjuvant treatment with dabrafenib and trametinib has been made before entering the study;
- V600E mutation-positive cutaneous melanoma;
- ≥ 18 years of age;
- Written informed consent signed.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Adana | Turkey (Türkiye) | Unknown status |
| - Coordinator of this site? Confirm its status | Ankara | Turkey (Türkiye) | Unknown status |
| - Coordinator of this site? Confirm its status | Antalya | Turkey (Türkiye) | Unknown status |
| - Coordinator of this site? Confirm its status | Bursa | Turkey (Türkiye) | Unknown status |
| - Coordinator of this site? Confirm its status | Diyarbakır | Turkey (Türkiye) | Unknown status |
| - Coordinator of this site? Confirm its status | Edirne | Turkey (Türkiye) | Unknown status |
| - Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
| - Coordinator of this site? Confirm its status | Izmir | Turkey (Türkiye) | Unknown status |
| - Coordinator of this site? Confirm its status | Kecioren Ankara | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.